Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, MI, USA.
Expert Rev Anticancer Ther. 2013 Sep;13(9):1053-64. doi: 10.1586/14737140.2013.829646.
Definitive chemoradiation (CRT) and laryngectomy followed by postoperative radiotherapy (RT) are both considered standard-of-care options for the management of advanced laryngeal cancer. While organ preservation with chemoradiotherapy is often the preferred up-front approach for appropriately selected candidates, the functional benefits of organ preservation must be carefully balanced against the considerable morbidity of salvage laryngectomy in patients who fail primary chemoradiation. Up-front identification of patients who are likely to require surgical salvage, therefore, is an important aim of any organ preserving approach in order to minimize morbidity while maximizing organ preservation. To this end, a strategy of 'chemoselection', using the primary tumor's response after 1 cycle of induction chemotherapy as an in vivo method of selecting responders for definitive chemoradiation while reserving primary surgical management for non-responders, has been employed extensively at our institution. The rationale, treatment results and future directions of this approach are discussed.
根治性放化疗(CRT)和喉切除术加术后放疗(RT)均被认为是治疗晚期喉癌的标准治疗选择。虽然对于适当选择的患者,放化疗保器官是首选的初始治疗方法,但在原发放化疗失败的患者中,保器官的功能益处必须与挽救性喉切除术的相当大的发病率仔细平衡。因此,在任何保器官方法中,明确识别可能需要手术挽救的患者是一个重要目标,以便在最大限度地保留器官的同时最小化发病率。为此,我们医院广泛采用了“化疗选择”策略,即在诱导化疗 1 个周期后,根据原发肿瘤的反应,作为选择接受根治性放化疗的应答者的体内方法,同时为无应答者保留原发手术治疗。本文讨论了这种方法的原理、治疗结果和未来方向。